Table 1 Patient characteristics.
Total number of patients | n = 13 |
|---|---|
Disease, n (%) | MCD 10/13 (77%) |
FSGS 3/13(23%) | |
Classification, n (%) | |
IRNS | 2/13 (15%) |
FRNS | 2/13 (15%) |
SDNS | 6/13 (46%) |
SRNS | 3/13 (23%) |
Previous therapies | |
Steroids | 13/13 (100%) |
CNI | 13/13 (100%) |
MMF | 9/13 (69%) |
Cyclophosphamide | 3/13 (23%) |
Other | 2/13 (15%) |
Gender female/male | 5 (38%) / 8 (62%) |
Age at diagnosis in years, median (IQR) | 11 (IQR 7–46) |
Age at first induction with RTX in years, median (IQR) | 31 (IQR 18–49) |
Baseline creatinine before RTX in mg/dL median (IQR) | 0.98 (IQR 0.71–1.25) |
eGFR FAS before RTX mL/min, median (IQR) | 93 (IQR 70–102) |
CKD stage (FAS) | |
Stage 1 | 6/13 (46%) |
Stage 2 | 3/13 (23%) |
Stage 3 | 1/13 (8%) |
Stage 4 | 1/13 (8%) |
Initial stage not available | 2/13 (15%) |
